RU2022101542A - Сокристаллы бензоата лития и их применения - Google Patents

Сокристаллы бензоата лития и их применения Download PDF

Info

Publication number
RU2022101542A
RU2022101542A RU2022101542A RU2022101542A RU2022101542A RU 2022101542 A RU2022101542 A RU 2022101542A RU 2022101542 A RU2022101542 A RU 2022101542A RU 2022101542 A RU2022101542 A RU 2022101542A RU 2022101542 A RU2022101542 A RU 2022101542A
Authority
RU
Russia
Prior art keywords
crystal
disorder
component
lithium benzoate
benzoate compound
Prior art date
Application number
RU2022101542A
Other languages
English (en)
Russian (ru)
Inventor
Гочуань Эмиль ТСАЙ
Чин-Чэн ВАН
Тиен-Лан СИЕХ
Юань-Чунь ЛО
Original Assignee
Сайньюрекс Интернэшнл (Тайвань) Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайньюрекс Интернэшнл (Тайвань) Корп. filed Critical Сайньюрекс Интернэшнл (Тайвань) Корп.
Publication of RU2022101542A publication Critical patent/RU2022101542A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • C07C57/10Sorbic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C07C57/44Cinnamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • C07C63/08Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2022101542A 2016-06-13 2017-06-13 Сокристаллы бензоата лития и их применения RU2022101542A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349582P 2016-06-13 2016-06-13
US62/349,582 2016-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018146423A Division RU2765625C2 (ru) 2016-06-13 2017-06-13 Сокристаллы бензоата лития и их применения

Publications (1)

Publication Number Publication Date
RU2022101542A true RU2022101542A (ru) 2022-02-03

Family

ID=60663075

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018146423A RU2765625C2 (ru) 2016-06-13 2017-06-13 Сокристаллы бензоата лития и их применения
RU2022101542A RU2022101542A (ru) 2016-06-13 2017-06-13 Сокристаллы бензоата лития и их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018146423A RU2765625C2 (ru) 2016-06-13 2017-06-13 Сокристаллы бензоата лития и их применения

Country Status (11)

Country Link
US (2) US10815184B2 (enExample)
EP (1) EP3468946A4 (enExample)
JP (1) JP6958923B2 (enExample)
KR (2) KR102338171B1 (enExample)
CN (1) CN109563024B (enExample)
CA (1) CA3027300C (enExample)
IL (1) IL263486B (enExample)
MX (1) MX2018015463A (enExample)
RU (2) RU2765625C2 (enExample)
TW (1) TWI736635B (enExample)
WO (1) WO2017215592A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563018A (zh) * 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途
US11376277B2 (en) 2020-06-01 2022-07-05 Celagenex Research (India) Pvt. Ltd. Synergistic medicinal compositions for treating dysfunctional D-serine signaling

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
EP1317434A4 (en) 2000-08-14 2005-06-22 Teva Pharma PREPARATION OF RISPERIDONE
EP1412515A2 (en) 2001-01-16 2004-04-28 Genset Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1628660A4 (en) 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR MODULATING THE CORTISOL SERUM MIRRORS
CN102010382A (zh) 2003-12-29 2011-04-13 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
EP1742624B1 (en) 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
MXPA06012777A (es) 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2505808A1 (en) * 2005-05-02 2006-11-02 Julie Danielle Globus Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080070984A1 (en) 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
US20130338199A1 (en) * 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
EP2310004A1 (en) * 2008-07-11 2011-04-20 Kareus Therapeutics SA Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
GB0813709D0 (en) 2008-07-26 2008-09-03 Univ Dundee Method and product
JP2010106001A (ja) * 2008-10-31 2010-05-13 Theravalues Corp Ppar活性化剤
CA2750028C (en) 2009-01-20 2019-05-07 Guochuan Emil Tsai Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
MX341072B (es) * 2010-07-23 2016-08-05 Grünenthal Gmbh * Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
CA2831086A1 (en) * 2011-03-24 2012-09-27 University Of South Florida Lithium compositions
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
US9120766B2 (en) * 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
DK2986618T3 (da) * 2013-04-19 2022-03-14 Univ South Florida Organiske anion-lithium-ion-co-krystalforbindelser og sammensætninger
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
JP6895752B2 (ja) * 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および/またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
SG11201507188QA (en) * 2014-03-24 2015-10-29 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment
CN103992320A (zh) 2014-05-26 2014-08-20 南京工业大学 一种混悬结晶制备药物共晶的方法
CA3176253A1 (en) * 2014-11-19 2016-05-26 Rush University Medical Center Use of cinnamic acid or sodium benzoate for treating lysosomal disorders
RU2582962C1 (ru) * 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
CN109563018A (zh) 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途

Also Published As

Publication number Publication date
EP3468946A1 (en) 2019-04-17
TWI736635B (zh) 2021-08-21
US20210107856A1 (en) 2021-04-15
CN109563024B (zh) 2023-06-06
KR102488927B1 (ko) 2023-01-13
CN109563024A (zh) 2019-04-02
KR102338171B1 (ko) 2021-12-09
EP3468946A4 (en) 2020-02-12
RU2765625C2 (ru) 2022-02-01
KR20190017939A (ko) 2019-02-20
KR20210142769A (ko) 2021-11-25
IL263486B (en) 2021-08-31
US11739046B2 (en) 2023-08-29
RU2018146423A3 (enExample) 2020-10-06
JP2019518757A (ja) 2019-07-04
RU2018146423A (ru) 2020-07-14
WO2017215592A1 (en) 2017-12-21
MX2018015463A (es) 2019-05-27
JP6958923B2 (ja) 2021-11-02
CA3027300A1 (en) 2017-12-21
TW201811321A (zh) 2018-04-01
CA3027300C (en) 2023-08-08
US20190177261A1 (en) 2019-06-13
IL263486A (en) 2019-01-31
US10815184B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
JP2021517901A (ja) アルコラート塩基の存在下でのニコチン酸エチルとn−ビニルピロリドンとの反応によるラセミ体ニコチンの調製及びその後の工程
JP2007510668A5 (enExample)
RU2022101542A (ru) Сокристаллы бензоата лития и их применения
CA3058496A1 (en) Crystal of benzofuran derivative free base and preparation method
KR102074535B1 (ko) 아미노산 화합물의 제조 방법
TWI725098B (zh) 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法
Lu et al. Dipeptide-derived multifunctional phosphonium salt as a catalyst to synthesize highly functionalized chiral cyclopentanes
JP2015505530A5 (enExample)
CN103224473A (zh) 一种三嗪环的制备方法
Liu et al. Ni (OAc) 2: a highly efficient catalyst for the synthesis of enaminone and enamino ester derivatives under solvent‐free conditions
JP2019518756A5 (enExample)
RU2019128576A (ru) Сокристаллы замещенных глициновых соединений и их применение
Ocampo et al. Catalyzed Reformatsky reactions with ethyl bromofluoroacetate for the synthesis of α-fluoro-β-hydroxy acids
KR101341715B1 (ko) 아미노-메틸 테트랄린 유도체의 합성 방법
Zhang et al. Zinc-mediated enantioselective addition of terminal 3-en-1-ynes to cyclic trifluoromethyl ketimines
RU2013158817A (ru) Способ синтеза и кристаллическая форма гидрохлорида 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)-ил]пропокси}бензамида и содержащие ее фармацевтические композиции
JP2018009100A5 (enExample)
CN1878766B (zh) 合成喹啉酮化合物的方法
JP2019518757A5 (enExample)
CN107602382A (zh) 一种有机催化合成手性芳基烯丙基醚类化合物的方法
JP6843116B2 (ja) アンドロゲン受容体阻害剤の結晶型及びその製造方法
JP6686050B2 (ja) ボラン錯体及びその製造法
CN106458944A (zh) 用于合成n‑甲基哌嗪二苯酚酰胺的方法及相关组合物
CN104496930B (zh) 一种光学纯度阿瑞匹坦原料药中间体制备方法
CN107266317A (zh) 一种手性芳基烯丙基醚类化合物及其合成方法